Background
Glioblastoma multiforme (GBM) is a highly malignant brain tumor characterized by rapid progression and poor patient outcomes. Despite advances in standard therapies, effective targeted treatments remain limited. UniProt entry Q86UE4 corresponds to a human protein with emerging evidence suggesting a role in GBM biology. However, this protein has not yet been explored in clinical development programs for GBM. Its expression profile in tumor tissues positions Q86UE4 as a putative target that warrants experimental validation.
Data-mining rationale
Q86UE4 was identified through a systematic cross-referencing of reviewed human UniProt entries annotated for glioblastoma multiforme against 724 microarray datasets from the NCBI Gene Expression Omnibus (GEO). Several GEO datasets (GDS:200317497, GDS:200273558, GDS:200320501, GDS:200318047, GDS:200318046) include expression data implicating Q86UE4 in GBM samples. The recurrence of this candidate across multiple independent datasets highlights its potential involvement in GBM molecular pathways and supports further investigation.
Why prior analyses may have missed this
Many of the GEO datasets relevant to Q86UE4 were generated before the adoption of advanced empirical-Bayes statistical methods such as limma, which improve the accuracy of differential expression analysis. Earlier analyses often lacked stringent multiple-testing correction, potentially leading to false negatives or underestimation of significance. Consequently, Q86UE4’s differential expression in GBM may have been overlooked. Re-analysis using limma with Benjamini-Hochberg false discovery rate control could better define its expression pattern and relevance.
Reasoning for further validation
To clarify the role of Q86UE4 in GBM, several experimental approaches are recommended. First, re-analyzing the matched GEO microarray datasets with limma and appropriate multiple-testing correction will provide a robust statistical assessment of differential expression. Validation of key findings by quantitative PCR in independent GBM cohorts will confirm reproducibility. Examining tissue specificity through resources like GTEx and the Human Protein Atlas will contextualize expression patterns. Network analyses using STRING or OmniPath may reveal functional pathways and interactions involving Q86UE4. If these data support its involvement, subsequent evaluation of druggability via DGIdb and ChEMBL will inform translational potential. Collectively, these steps will determine whether Q86UE4 merits prioritization for further preclinical and clinical research in glioblastoma.